Sonoma Pharmaceuticals (SNOA) Net Income towards Common Stockholders (2010 - 2025)
Sonoma Pharmaceuticals (SNOA) recorded quarterly Net Income towards Common Stockholders of -$819000.0 in Q4 2025, down 53.37% quarter-over-quarter from -$534000.0 in Q3 2025, and up 11.75% on a YoY basis from -$732914.2 in Q4 2024.
Sonoma Pharmaceuticals (SNOA) Net Income towards Common Stockholders (2010 - 2025) Analysis & Trends
Sonoma Pharmaceuticals' Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$819000.0 for Q4 2025.
- In Q4 2025, Net Income towards Common Stockholders rose 11.75% year-over-year to -$819000.0; the TTM figure through Dec 2025 stood at -$3.4 million (up 10.09% YoY), while the FY2025 annual figure was -$3.5 million, up 28.5% from the prior year.
- Net Income towards Common Stockholders was -$819000.0 for Q4 2025 at Sonoma Pharmaceuticals, down from -$534000.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$100000.0 in Q3 2021 to a low of -$1.9 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged -$1.0 million across 5 years, with a median of -$1.0 million in 2022.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders sank 917.0% in 2022, then jumped 58.89% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$100000.0 in 2021, then sank by 1839.0% to -$1.9 million in 2022, then jumped by 55.34% to -$866000.0 in 2023, then decreased by 7.16% to -$928000.0 in 2024, then increased by 11.75% to -$819000.0 in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$819000.0 (Q4 2025), -$534000.0 (Q3 2025), and -$1.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Sonoma Pharmaceuticals | 1.87 Mn | -693,829.94 | 1.65 Mn | -819,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -819,000.00 |
| Sep 30, 2025 | -534,000.00 |
| Jun 30, 2025 | -1.24 Mn |
| Mar 31, 2025 | -776,000.00 |
| Dec 31, 2024 | -928,000.00 |
| Sep 30, 2024 | -610,000.00 |
| Jun 30, 2024 | -1.14 Mn |
| Mar 31, 2024 | -1.07 Mn |
| Dec 31, 2023 | -866,000.00 |
| Sep 30, 2023 | -1.48 Mn |
| Jun 30, 2023 | -1.42 Mn |
| Mar 31, 2023 | -1.31 Mn |
| Dec 31, 2022 | -1.94 Mn |
| Sep 30, 2022 | -1.02 Mn |
| Jun 30, 2022 | -887,000.00 |
| Sep 30, 2021 | -100,000.00 |
| Jun 30, 2021 | -1.10 Mn |
| Dec 31, 2020 | -24,000.00 |
| Sep 30, 2020 | -31,000.00 |
| Jun 30, 2020 | 949,000.00 |